Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Chemotherapy in Second-Line pNET-LM
NCT07835893Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in Pancreatic neuroendocrine tumor (PanNET), sponsored by Peking Union Medical College Hospital. Started Jan 2026; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT07835893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835893.